Chronic Pain Market Grows Amid Rising Incidence of Neuropathic Conditions and Demand for Non-Opioid Therapies, 2025-2032 | Pfizer Inc., Johnson & Johnson, GlaxoSmithKline PLC

The Chronic Pain Market is experiencing significant transformation driven by rising prevalence globally and advancements in therapeutic modalities. Increasing incidences of musculoskeletal disorders, neuropathic pain, and cancer-related pain are intensifying demand for chronic pain management solutions. The healthcare industry's expanding focus on patient-centric approaches and personalized medicine is further reshaping market dynamics. The Global Chronic Pain Market size is estimated to be valued at USD 77.30 billion in 2025 and is expected to reach USD 125.84 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Request Sample Copy of this Report (Use Corporate eMail ID to Get Higher Priority) at : https://www.coherentmarketinsights.com/insight/request-sample/4767

➤ Actionable insights

● In 2024, global production capacity of novel analgesics increased by 12%, responding to a 15% rise in demand from North American and Asia Pacific healthcare sectors.
● Pricing dynamics show a 5% average increase in chronic pain drug pricing from 2023 to 2024, influenced by higher R&D expenses and raw material costs.
● Import volumes of non-opioid analgesics in Europe grew by 9% in 2024, indicating shifting preferences driven by regulatory restraints on opioids.
● Multi-indication use cases, including chronic back pain and fibromyalgia, accounted for over 60% of market revenue in 2024, confirming expansion opportunities across therapeutic areas.
● Micro-segmentation reports indicate fast-growing nanoformulated drug candidates entering clinical trials, with over 20 such therapies projected by 2026, representing potential future market drivers.

❖ Market segment and regional coverage

○ By Pain Type: Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Post-operative Pain, Others
○ By Treatment Type: Pharmacological, Non-pharmacological, Interventional Procedures, Combination Therapies, Others
○ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Others

Regional and Country Analysis:

○ North America: U.S. and Canada
○ Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
○ Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
○ Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
○ Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA

Get the Sample Copy of the Research Report: https://www.coherentmarketinsights.com/insight/request-sample/4767

✔ Key players

» Pfizer Inc.
» Johnson & Johnson
» GlaxoSmithKline PLC
» Bayer AG
» Novartis AG
» Endo Pharmaceuticals
» Bristol-Myers Squibb
» Eli Lilly and Company
» Teva Pharmaceutical Industries Ltd.
» Reckitt Benckiser Group plc
» Medtronic plc
» AstraZeneca PLC
» Becton, Dickinson and Company
» AbbVie Inc.
» Horizon Therapeutics
» Mallinckrodt Pharmaceuticals
» Zynerba Pharmaceuticals
» Neurocrine Biosciences
» Sorrento Therapeutics
» Cypress Pharmaceutical

Several leading market players have embarked on strategic collaborations and acquisitions to enhance their product pipeline and market reach. For example, Eli Lilly's 2024 partnership with a biotech firm accelerated the commercial launch of an innovative non-opioid pain drug, boosting its market revenue notably in North America. Similarly, Pfizer's expansion of its manufacturing capabilities in Asia Pacific in late 2023 supported enhanced supply-chain efficiencies, increasing its industry share regionally.

➤ Growth factors

✓ Rising geriatric populations globally, with a 2024 WHO report indicating a 10% growth in age-related chronic pain cases.
✓ Increased adoption of combination therapies integrating pharmacological and non-pharmacological treatments, driving higher treatment adherence and market demand.
✓ Expanding investment in pain neuroscience research enhancing drug efficacy and targeting underlying pain mechanisms with higher precision.
✓ Regulatory encouragement for opioid alternatives, exemplified by FDA approvals of novel analgesics between 2023-2024, supporting broader market growth.

❖ Market trends

⇨ The shift towards personalized pain management solutions has been accelerated by AI-driven diagnostics and digital therapeutics, with 2024 studies showing a 20% improvement in patient outcomes using these technologies.
⇨ Increasing prevalence of minimally invasive interventional pain procedures, with hospital adoption rates rising by 18% in Europe and North America during 2024.
⇨ The rise of telemedicine platforms offering chronic pain monitoring and management services is creating new revenue streams, supporting sustained market expansion.
⇨ Growing consumer awareness about non-opioid options is transforming demand patterns, reflected in a 22% rise in market revenue from biologics and targeted therapies in 2024.

✒ Key takeaways

→ The chronic pain market size is projected to grow steadily, driven by significant industry share expansion in pharmacological treatments.
→ Neuropathic pain remains a dominating subsegment due to its complex nature and high unmet medical needs.
→ Hospital pharmacies continue to be the primary distribution channel, supported by increased adoption of in-hospital treatments.
→ North America supports robust market growth through advanced healthcare infrastructure and high investment in pain research.
→ Asia Pacific shows strong potential growth opportunities, encouraged by rising healthcare access and patients' willingness for modern treatments.
→ Europe's regulatory environment fosters innovation in safer, opioid-free pain management therapies, impacting industry trends.

Buy the Complete Report with an Impressive Discount (Up to 25% Off) at: https://www.coherentmarketinsights.com/insight/buy-now/4767

❓ Frequently Asked Questions

1. Who are the dominant players in the chronic pain market?
The chronic pain market is led by companies such as Pfizer Inc., Johnson & Johnson, GlaxoSmithKline PLC, Bayer AG, and Novartis AG, among others, all of which are pursuing diversified portfolios and strategic expansions to capture increasing market share.

2. What will be the size of the chronic pain market in the coming years?
The chronic pain market size is forecasted to reach USD 125.84 billion by 2032, growing at a CAGR of 7.2% from USD 77.30 billion in 2025, reflecting strong market growth influenced by advancing therapies and expanding patient base.

3. Which end-user industry has the largest growth opportunity?
The healthcare sector focusing on musculoskeletal and neuropathic pain management segments offers the largest growth opportunities due to rising patient prevalence and significant unmet needs in these therapeutic areas.

4. How will market development trends evolve over the next five years?
Market trends emphasize personalized medicine, increased adoption of non-opioid treatments, expansion of digital therapeutics, and minimally invasive procedures, all contributing to more targeted and effective chronic pain management.

5. What is the nature of the competitive landscape and challenges in the chronic pain market?
The competitive landscape is characterized by innovation-driven players focusing on R&D investments, strategic partnerships, and diversification to overcome challenges such as regulatory restrictions on opioids and pricing pressures.

6. What go-to-market strategies are commonly adopted in the chronic pain market?
Market companies typically implement combination strategies involving strategic alliances, geographical expansion, product portfolio diversification, and leveraging digital health solutions to optimize market penetration and revenue growth.

Author of this Marketing PR:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

📞 Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
U.S.: + 12524771362
U.K.: +442039578553
AUS: +61-2-4786-0457
INDIA: +91-848-285-0837

About CMI:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

This release was published on openPR.